Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2E1 | P05181 | 3/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.33 |
| ▸ | CPB1 | P15086 | 2/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | ICMT | O60725 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4172725 | 0.84 | HPGDS (0.38) | CYP2E1CYP2A6CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL7197545 | 0.83 | CYP2E1 (0.45) | CYP2E1CYP2A6CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL31282496 | 0.82 | CYP2A6 (0.65) | CYP2E1CYP2A6CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL708867 | 0.82 | CYP2A6 (0.65) | CYP2E1CYP2A6CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL2386354 | 0.81 | CYP2A6 (0.63) | CYP2E1CYP2A6CYP2C9CYP2B6CYP2C19 | |
| Hydrochloric Acid SCHEMBL1149529 | 0.81 | CYP2A6 (0.63) | CYP2E1CYP2A6CYP2C9CYP2B6CYP2C19 | |
| Ammonia Solution, Strong SCHEMBL1149566 | 0.81 | CYP2A6 (0.63) | CYP2E1CYP2A6CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL4871159 | 0.81 | CYP2E1 (0.41) | CYP2E1CYP2A6CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL4869521 | 0.79 | PDE10A (0.46) | CYP2E1CYP2A6CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL27585613 | 0.79 | CYP2E1 (0.42) | CYP2E1CYP2A6CYP2C9CYP2B6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005047281-A1 | NOVEL HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2005-05-26 | — | — | WO | claimed |
| US-7332476-B2 | Pyridyl substituted ketolide antibiotics | NOVARTIS AG (CH) | 2008-02-19 | — | — | US | disclosed |
| WO-2005047281-A1 | NOVEL HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2005-05-26 | — | — | WO | disclosed |
| US-20050009764-A1 | Pyridyl substituted ketolide antibiotics | CHIRON CORPORATION (US) | 2005-01-13 | — | — | US | disclosed |
| US-6756359-B2 | ADMINISTERING A 14 MEMBERED MACROLIDE AND KETOLIDE ANTIBIOTICS CONTAINING C12 MODIFICATIONS TO A PATIENT SUFFERING FROM BACTERIAL INFECTIONS | CHIRON CORPORATION | 2004-06-29 | — | — | US | disclosed |
| US-20030125266-A1 | C12 Modified erythromycin macrolides and ketolides having antibacterial activity | CHU DANIEL (US) | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009764-A1 | Pyridyl substituted ketolide antibiotics | PKLR, KHK, PGD | CYP2E1 323/4885CYP2A6 57/4885CYP2C9 10/4885 |
| US-20030125266-A1 | C12 Modified erythromycin macrolides and ketolides having antibacterial activity | MRPL21, CYP51A1, CEL | CYP2E1 362/4885CYP2A6 68/4885CYP2C9 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.